Remetinostat: Additional Ph II data

Data from 60 patients with stage Ia-IIa CTCL in an open-label, U.S. Phase II trial showed that once-daily 1%, twice-daily 0.5% and twice-daily 1% topical remetinostat for 26-52 weeks led to confirmed CAILS response rates of 20%, 25% and 40%, respectively. There was 1 complete response at the twice-daily 1% remetinostat dose...